ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial

GlobeNewswire11/20 20:55

ZyVersa Therapeutics Q3 2024 GAAP EPS $(2.43) Beats $(3.70) Estimate

Benzinga11/14 21:14

ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update

Globe Newswire11/14 21:10

Press Release: ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update

Dow Jones11/14 21:10

10-Q：Q3 2024 四半期報告書

SEC11/14 21:06

Dow Jumps 400 Points; Yum! Brands Posts Downbeat Earnings

Benzinga11/06 03:32